For research use only. Not for therapeutic Use.
Managlinat dialanetil (MB06322) is an orally bioavailable inhibitor of fructose 1,6-bisphosphatase (FBPase) for the treatment of type 2 diabetes[1] [2].
Managlinat dialanetil dose-dependently inhibits GNG as well as lower basal and postprandial blood glucose levels in Zucker diabetic fatty (ZDF) rats after oral administration[1].
| Catalog Number | I007904 |
| CAS Number | 280782-97-0 |
| Synonyms | ethyl (2S)-2-[[[5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphanyl]amino]propanoate |
| Molecular Formula | C21H33N4O6PS |
| Purity | ≥95% |
| InChI | InChI=1S/C21H33N4O5PS/c1-7-28-19(26)13(5)24-31(25-14(6)20(27)29-8-2)17-10-9-15(30-17)18-16(11-12(3)4)32-21(22)23-18/h9-10,12-14,24-25H,7-8,11H2,1-6H3,(H2,22,23)/t13-,14-/m0/s1 |
| InChIKey | JGCMEVUWRCNKKE-KBPBESRZSA-N |
| SMILES | CCOC(=O)C(C)NP(C1=CC=C(O1)C2=C(SC(=N2)N)CC(C)C)NC(C)C(=O)OCC |
| Reference | [1]. Wang Y, et al. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2007 Oct;8(10):849-58. |
